JPH02221232A - Readily drinkable medicine composition - Google Patents

Readily drinkable medicine composition

Info

Publication number
JPH02221232A
JPH02221232A JP4476889A JP4476889A JPH02221232A JP H02221232 A JPH02221232 A JP H02221232A JP 4476889 A JP4476889 A JP 4476889A JP 4476889 A JP4476889 A JP 4476889A JP H02221232 A JPH02221232 A JP H02221232A
Authority
JP
Japan
Prior art keywords
soluble fiber
tablets
product
reduced
water soluble
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP4476889A
Other languages
Japanese (ja)
Inventor
Michio Hanai
花井 通夫
Kiyomi Kamata
鎌田 清美
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wakodo Co Ltd
Original Assignee
Wakodo Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wakodo Co Ltd filed Critical Wakodo Co Ltd
Priority to JP4476889A priority Critical patent/JPH02221232A/en
Publication of JPH02221232A publication Critical patent/JPH02221232A/en
Pending legal-status Critical Current

Links

Landscapes

  • Medicinal Preparation (AREA)

Abstract

PURPOSE:To obtain a readily drinkable medicine composition reduced in unpleasant feeling in mouth by blending a water soluble fiber alone or in combination of reduced malt sugars. CONSTITUTION:A water soluble fiber, e.g. polydextrose or pine fiber or the water soluble fiber and reduced malt sugar are blended into a solid preparation, semi-solid preparation and liquid preparation. When the above-mentioned ingredient is used as a binder for solid agent or disintegrator, medicine is readily dissolved and further bitter taste of main medicine added can be masked.

Description

【発明の詳細な説明】 〔産業上の利用分野〕 本発明は、上記成分を固形製剤、半固形製剤ならびに液
状製剤に配合することによって、該製剤を幼小児、老人
などが容易に服用することの出来る組成物に関する。
[Detailed Description of the Invention] [Industrial Field of Application] The present invention provides a formulation that can be easily taken by young children, the elderly, etc. by incorporating the above-mentioned ingredients into solid, semi-solid, and liquid preparations. The present invention relates to a composition that can be used.

〔従来の技術〕[Conventional technology]

現在、医薬品製剤には、錠剤(裸錠、フィルムコーティ
ング錠、塘衣錠)、散剤、顆粒剤、トローチ剤、シロッ
プ剤、舐剤、経口補液なとがあり、これらは通常一定量
の活性成分(主薬)に賦形剤、結合剤、滑沢剤、崩壊剤
、矯味、矯臭剤などの補助剤を混合することによって製
造される。
Currently, pharmaceutical formulations include tablets (uncoated tablets, film-coated tablets, and coated tablets), powders, granules, lozenges, syrups, lozenges, and oral refills, which usually contain a fixed amount of the active ingredient. It is manufactured by mixing the main drug with auxiliary agents such as excipients, binders, lubricants, disintegrants, flavoring agents, and flavoring agents.

〔発明が解決しようとする問題点〕[Problem that the invention seeks to solve]

しかしながら、このような製剤中には、結合剤、崩壊剤
、賦形剤として乳糖、澱粉、微結晶セルロース等が配合
されているにもかかわらず、舌ざわり、味、におい等に
好ましくないものが認められる。
However, although these preparations contain lactose, starch, microcrystalline cellulose, etc. as binders, disintegrants, and excipients, they have been found to have undesirable texture, taste, odor, etc. It will be done.

とくに、幼小児、老人にとっては、味、溶解性、硬度等
の好ましくない剤型、とりわけ散剤は幼小児、老人では
服用時に口喉部に付着し之り、口中での拡散の為に、不
快感を覚え、服用拒否の原因になる事が多い。
In particular, for young children and the elderly, dosage forms that are unfavorable in terms of taste, solubility, hardness, etc., especially powders, may stick to the mouth and throat of young children and the elderly when they are taken, and may be undesirable due to dispersion in the mouth. It gives a pleasant sensation and often causes people to refuse to take it.

ま九、胃腸障害の患者や糖尿病患者などカロリー制限を
受けている患者においては、砂糖、ブドウ糖類を主体と
して配合されているチーアプル錠、舐剤、シロップ剤並
びに経口補液なとは好ましくない事が考えられる。
Also, for patients who are on calorie restriction, such as those with gastrointestinal disorders or diabetes, Cheapul tablets, lozenges, syrups, and oral fluid rehydration, which are mainly formulated with sugar and glucose, may not be desirable. Conceivable.

本発明が提供する組成物は、味、溶解性、のみ易さ、口
中での不快感を改善する為の主素材として、水溶性繊維
ま之は、水溶性繊維および還元麦芽糖類を含有すること
を特徴とする組成物である。
The composition provided by the present invention contains water-soluble fiber and reduced maltose as main ingredients to improve taste, solubility, ease of swallowing, and discomfort in the mouth. A composition characterized by:

ここで、この組成物とは、富態において固型であは必ず
しも固型でない半固型組放物(プリン、ゼリー ヨーグ
ルト)、液状(水剤、・シロラグ剤。
Here, this composition refers to semi-solid compositions (pudding, jelly, yogurt) that are solid in their rich form, but not necessarily solid (pudding, jelly, yogurt), and liquid (water preparations, silage agents).

エリキシル剤、経口補液、輸液、経管栄養剤)、飴状等
の組成物を包含する。
This includes compositions such as elixirs, oral rehydration fluids, infusions, tube feedings), and lozenges.

水溶性繊維とは、ポリデキストロースまたは・9インフ
アイバーその他であり、ポリデキストロースは本邦にお
いてファイザー株式会社の提供する商品名であり、可食
性ポリカルゲン酸(たとえばクエン酸)全触媒並びに架
橋剤にして、グルコースまたはマルトースを溶融状態で
重合させて得られる分子量的1500〜1800の水溶
性多糖類である。(製法特許は米国特許第375616
5号明細書に記載されている。) パインファイバーは、松谷化学工業所裂の商品名であり
、工業用焙焼デキストリン金生産工程中で水和させ、高
純度精製したもので、難消化性成分55%を含む難消化
性fキストリンである。
The water-soluble fiber is polydextrose or 9-in-fiber, etc. Polydextrose is a trade name provided by Pfizer Inc. in Japan, and is made of edible polycargenic acid (for example, citric acid) as a total catalyst and a crosslinking agent. It is a water-soluble polysaccharide with a molecular weight of 1500 to 1800 obtained by polymerizing glucose or maltose in a molten state. (The manufacturing process patent is U.S. Patent No. 375616.
It is described in the specification of No. 5. ) Pine fiber is the trade name of Matsutani Chemical Industry Co., Ltd., and is a highly purified product that is hydrated during the industrial roasted dextrin gold production process and is an indigestible f-xtrin containing 55% of indigestible components. It is.

還元麦芽糖類とは還元麦芽糖(無水物も含む)及び還元
麦芽糖水飴であり、その他必要に応じてソルビット、マ
ルピット、D−マンニット、グルコース、アスコルビン
酸、クエン酸、DL−リンゴ酸、エリソルビン酸、炭酸
水素ナトリウムt−添加することができる。
Reduced maltose refers to reduced maltose (including anhydrous) and reduced maltose starch syrup, and as necessary, sorbitol, marpit, D-mannite, glucose, ascorbic acid, citric acid, DL-malic acid, erythorbic acid, Sodium bicarbonate can be added.

水溶性繊維は、固型剤の結合剤あるいは崩壊剤、矯味、
矯臭剤として0.5〜80%で用いることができる。
Water-soluble fiber is a binder or disintegrant for solids, a flavoring agent,
It can be used as a flavoring agent at 0.5 to 80%.

ま九、水溶性繊維および還元麦芽糖類の配合比率は、前
者は0.5〜80%、後者は2〜80%が適当である。
The appropriate blending ratio of water-soluble fiber and reduced maltose is 0.5 to 80% for the former and 2 to 80% for the latter.

本発明の製剤に配合される補助剤としては、従来内服剤
として用いられるものは、とくに本発明の目的達成の妨
げにならない範囲で含有させることができる。具体的に
は、結合剤として乳糖、バレイシw7′ンプン、トウモ
ロコシデンゾン、ガキストリン、アラビアゴム、ゼラチ
ン、n製セラック、ヒドロキシプロピルセルロース、ヒ
ドロキシグロビルメチルセルロース、ソルビット、ヒド
ロキシプロピルスターチ、カルゼキシメチルセルロース
ナトリウム、結晶セルロース、エチルセルロース、ポリ
ビニルピロリドン、トラがント、ポリエチレングリコー
ル、脂肪酸グリセリンエステル等。
As adjuvants to be incorporated into the formulation of the present invention, those conventionally used as internal preparations can be included, particularly within a range that does not interfere with achieving the objectives of the present invention. Specifically, as a binder, lactose, barley starch, corn starch, gakistrin, gum arabic, gelatin, N shellac, hydroxypropyl cellulose, hydroxyglobil methyl cellulose, sorbitol, hydroxypropyl starch, calxexy methyl cellulose sodium, Crystalline cellulose, ethyl cellulose, polyvinylpyrrolidone, triglyceride, polyethylene glycol, fatty acid glycerin ester, etc.

ま九、滑沢剤として、メルク、サラシミツロウ、硬化油
、軽質無水ケイ酸、含水二酸化ケイ素、スま友、崩壊剤
として、カルブキシメチルスターチナトリウム、カンテ
ン末、ベントナイト等。その他香料。その他の素材。
9. As a lubricant, Merck, beeswax, hydrogenated oil, light anhydrous silicic acid, hydrated silicon dioxide, smear, as a disintegrant, sodium carboxymethyl starch, agar powder, bentonite, etc. Other fragrances. Other materials.

〔作用〕[Effect]

本発明の製剤は1口中での不快感を軽減し、固型剤にあ
っては結合剤、崩壊剤として用いれば溶解し易く、更に
添加した主薬の苦味をマスクするのに従来の方法より有
効な発明であり、とくに幼小児、老人に有用な製剤であ
る。
The formulation of the present invention reduces discomfort in the mouth, and when used as a binder or disintegrant for solid formulations, it dissolves easily, and is more effective than conventional methods in masking the bitterness of the added active ingredient. This invention is particularly useful for young children and the elderly.

〔実施例〕〔Example〕

次に実施例を挙げて、本発明を更に具体的に説明するが
、本発明はこれによって限定されるものではない。
EXAMPLES Next, the present invention will be explained in more detail with reference to Examples, but the present invention is not limited thereto.

実施例1 小児用鎮うん薬(チュアブル錠) 塩酸メクリジン含有の直径5.7 m 、重量100m
gの錠剤を打錠成形した。また、比較品として従来の結
合剤ないし崩壊剤として用いられるハイドロキシグロビ
ルセルロース(RPC−L ) 含有(D錠剤を成形し
た。得られた錠剤について、錠剤硬度計を用いて硬度測
定し、″また日本薬局方に基づき崩壊試験を行った結果
、本発明品は比較品、市販品に比べ、硬度、崩壊性が良
好であった。
Example 1 Pediatric antidepressant (chewable tablet) Contains meclizine hydrochloride, diameter 5.7 m, weight 100 m
g tablets were compressed into tablets. In addition, as a comparative product, tablets containing hydroxyglobil cellulose (RPC-L), which is used as a conventional binder or disintegrant, were molded. The hardness of the obtained tablets was measured using a tablet hardness tester. As a result of performing a disintegration test based on the Japanese Pharmacopoeia, the product of the present invention had better hardness and disintegrability than comparative products and commercially available products.

を行った結果、本発明品は比較品に比べて崩壊性が良好
であシ、あわせて行っ几官能試験()9ネル15人)の
結果においても、とくにピヒイズス薗特有の味がマスキ
ングされ、のみ易さも良好であった。
As a result, the product of the present invention had better disintegration properties than the comparative product, and the results of a sensory test (2015), which was conducted on 9 people (15 people), showed that the unique taste of pihizusu was masked, It was also easy to swallow.

実施例2 ビフィズス菌錠剤 (組成)ビフィズス歯末        25重量%還
元麦芽糖        40 l ポリデキストロース      30 N炭酸水素ナト
リウム     IN アスコルビン酸        3 〃ステアリン酸マ
グネシウム    lNヨーグルトフレーバー    
 0.1 1上記の各組成を混合し、次いで直径13m
の平型隅丸、重1500m5に打錠成形した。ま几比較
品として市販のビフィズス菌友剤を細粒化し、これを打
錠成形した。
Example 2 Bifidobacterium tablet (composition) Bifidobacteria powder 25% by weight reduced maltose 40 l Polydextrose 30 N Sodium bicarbonate IN Ascorbic acid 3 Magnesium stearate IN Yogurt flavor
0.1 1 Mix each of the above compositions, then 13 m diameter
It was compressed into tablets with flat rounded corners and a weight of 1500 m5. As a comparison product, a commercially available bifidobacterial agent was pulverized into fine particles, and the resultant was compressed into tablets.

得られ九錠剤について、錠剤硬度計を用いて硬度を測定
し、また日本薬局方に基づき、崩壊試験官能試験 実施例3 カルシウム剤 カルシウム末を常法により試作し、従来品との比較をパ
ネル15人で官能試験全行っ之。
The hardness of the resulting nine tablets was measured using a tablet hardness tester, and based on the Japanese Pharmacopoeia, disintegration test sensory test Example 3 Calcium agent calcium powder was prototyped using a conventional method and compared with the conventional product in Panel 15. All sensory tests were conducted on humans.

表 官能評価 官能試験 表の結果より、本発明品は味、のみ易さともに従来品に
比較して、十分満足し得る結果であっ之。
Table: Sensory Evaluation From the results of the sensory test table, the product of the present invention has sufficiently satisfactory results in both taste and ease of swallowing when compared to conventional products.

実施例4 チ、アグル錠 ビタミンCのチュアグル錠を試作し、従来品との比較t
パネル7人で官能試験を行った。
Example 4: Prototype Chuagle tablets of vitamin C were made and compared with conventional products.
A sensory test was conducted with a panel of seven people.

茨の結果−より、本発明品が最も好まれ、硬さ、味、溶
は易さについても、本発明品は従来品と比較して十分満
足し得る結果であった。
According to the results, the product of the present invention was the most preferred, and the product of the present invention had sufficiently satisfactory results in terms of hardness, taste, and ease of dissolution compared to the conventional product.

実施例5 シロップ剤 常法により次のシロンfを装造し、発明品と単シロップ
で裂し次比較品をパネル1o人で官能試験比較を行った
Example 5 Syrup The following Silon F was prepared in a conventional manner, and the invention product and the next comparative product were split with simple syrup and a sensory test was performed on a panel of 10 people.

苦味金有するアセトアミノフェンの従来のシロップを本
発明品と比較した結果、本発明品は比較品に比し、明ら
かに苦味の軽減が認められた。
As a result of comparing a conventional syrup of acetaminophen having a bitter taste with the product of the present invention, it was found that the product of the present invention had a clearly reduced bitterness compared to the comparative product.

実施例6 飴状の剤形であるマルツエキスは、乳幼児便秘治療剤で
あり、デンプンを麦芽で糊化し、炭酸カリウムを加え、
減圧濃縮し定木飴状のもので麦芽糖金60%以上を含む
。このマルツエキスにポリデキストロースを加えた後、
水を加え溶解し、これを凍結乾燥後粉状混合物を得る。
Example 6 Malt extract, which is in the form of a candy, is a treatment for infant constipation, and is made by gelatinizing starch with malt, adding potassium carbonate,
Concentrated under reduced pressure, it is made into a candy-like substance containing more than 60% maltose gold. After adding polydextrose to this malt extract,
Water is added and dissolved, and this is freeze-dried to obtain a powdery mixture.

本発明品2,4と従来品(飴状のマルツエキス)を20
人のツヤネルで比較し九結果、いずれも従来品より日中
でとけ易く、味、のみ易さともに良好であっ九。
Invention products 2 and 4 and conventional product (candy-like malt extract)
When compared with human glossy gels, all of the products melted more easily during the day than conventional products, and were both better in taste and ease of swallowing.

官能試験 実施例7 ゼリー ゼラチン        3 重量% アセトアミノ7エン    0.165  If還元麦
芽糖     15 〃 ポリブーVストロース         1    〃
炭酸水素ナトリウム     0.1   /f水  
         残  部 アセトアミノフェン、還元麦芽糖、ポリデキストロース
’1100−の水に約70℃で保温しながら溶解させ、
これに炭酸水素ナトリウムを加え、ゼラチンに混ぜ、4
℃で30〜60分保存凝固させる。
Sensory test example 7 Jelly gelatin 3% by weight Acetamin 7ene 0.165 If reduced maltose 15 〃 Polybu-V strose 1 〃
Sodium hydrogen carbonate 0.1/f water
The remaining acetaminophen, reduced maltose, and polydextrose '1100- were dissolved in water while keeping warm at about 70°C.
Add sodium bicarbonate to this and mix with gelatin, 4
Store at ℃ for 30-60 minutes to solidify.

本発明品は、薬物の苦味も軽減され、幼小児、老人が極
めてのみやすい組成物である。
The product of the present invention has a reduced bitter taste and is a composition that is extremely easy for young children and the elderly to swallow.

実施例8 錠剤のフーティング 転勤流動層造粒コーティング装置(岡田精工展)の流動
槽内に苦味を有するアセトアミノフェンの錠剤(直径5
.7 m ) ’k 500 fi入れ、槽底の円板を
回転しながら、スリットエアーから空気をふき出して、
流動層内の温度を45〜50℃に偶節しながら錠剤を流
動させ、以下のfilに示す組成のコーティング剤をエ
アー噴4式スプレーがンにより、12〜14ゴ/min
の割合で噴霧した。
Example 8 Acetaminophen tablets with a bitter taste (diameter 5
.. 7 m) Put in 'k 500 fi, blow out the air from the slit air while rotating the disk at the bottom of the tank,
The tablets were fluidized while controlling the temperature in the fluidized bed at 45 to 50°C, and a coating agent having the composition shown in the following file was applied at 12 to 14 g/min using an air jet 4 type spray gun.
It was sprayed at a rate of

本発明の組成のコーティング剤は、従来の水溶性コーテ
ィング剤と比較し、苦味のマスキングは良好であシ、摩
損度、粘着錠剤数も少なく良好な結果であった。(表2
) 〔発明の効果〕 本発明の水溶性繊維ま几は、水溶性繊維および還元麦芽
糖によりて製した製剤は、従来の賦形剤を配合し次回薬
品製剤に比較し1日中での不快感を軽減した服用しやす
い製剤であり、幼小児や老人、または低カロリーを必要
とされる糖尿病患者等に適した組成物である。
Compared to conventional water-soluble coating agents, the coating agent with the composition of the present invention had better masking of bitterness, lower friability, and lower number of adhesive tablets. (Table 2
) [Effects of the Invention] The water-soluble fiber matrix of the present invention shows that the formulation made from water-soluble fiber and reduced maltose has less discomfort during the day compared to the next drug formulation containing conventional excipients. It is an easy-to-take formulation with reduced calorie intake, and is suitable for infants, children, the elderly, and diabetic patients who require a low calorie diet.

イノく、ヂ1人づ確7理」= 大計す尺 表1 コーティング溶液組成 部はいずれも重量%を示す。Inoku, 7 principles for each person = A rough measure of scale Table 1 Coating solution composition All parts indicate weight %.

表2 コーチ4フフ錠の評価 一甲寺Iの舌体t−認めるTable 2 Evaluation of Coach 4 Fufu Tablets Ikkoji I tongue body t- recognized

Claims (2)

【特許請求の範囲】[Claims] (1)水溶性繊維または、水溶性繊維および還元麦芽糖
類を配合することを特徴とする医薬組成物。
(1) A pharmaceutical composition characterized by containing water-soluble fiber or water-soluble fiber and reduced maltose.
(2)水溶性繊維および還元麦芽糖類を配合することを
特徴とする組成物。
(2) A composition characterized by containing water-soluble fiber and reduced maltose.
JP4476889A 1989-02-23 1989-02-23 Readily drinkable medicine composition Pending JPH02221232A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP4476889A JPH02221232A (en) 1989-02-23 1989-02-23 Readily drinkable medicine composition

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP4476889A JPH02221232A (en) 1989-02-23 1989-02-23 Readily drinkable medicine composition

Publications (1)

Publication Number Publication Date
JPH02221232A true JPH02221232A (en) 1990-09-04

Family

ID=12700600

Family Applications (1)

Application Number Title Priority Date Filing Date
JP4476889A Pending JPH02221232A (en) 1989-02-23 1989-02-23 Readily drinkable medicine composition

Country Status (1)

Country Link
JP (1) JPH02221232A (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001294524A (en) * 2000-04-12 2001-10-23 Taisho Pharmaceut Co Ltd Oral solid preparation containing acetaminophen

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS63502558A (en) * 1986-02-08 1988-09-29 ザ ハワ−ド ファウンデ−ション Sweet confectionery products and their manufacturing methods

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS63502558A (en) * 1986-02-08 1988-09-29 ザ ハワ−ド ファウンデ−ション Sweet confectionery products and their manufacturing methods

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001294524A (en) * 2000-04-12 2001-10-23 Taisho Pharmaceut Co Ltd Oral solid preparation containing acetaminophen

Similar Documents

Publication Publication Date Title
JP4336021B2 (en) Orally disintegrating tablet and method for producing the same
JP2874967B2 (en) Pharmaceutical water suspension for drug actives essentially insoluble in water
TW501930B (en) Pharmaceutical, orally applicable composition with antacid active substance
US6432442B1 (en) Chewable product
KR900007468B1 (en) New Glucose Delivery Compositions of Active Substances
JP2820319B2 (en) Rapidly disintegrating multiparticulate tablets
US20090304824A1 (en) Rapid-Melt Compositions, Methods of Making Same and Methods of Using Same
WO1999018936A1 (en) Quickly soluble solid preparations
JP2012072166A (en) Composition and method for mucosal delivery
WO2002002080A1 (en) Rapid-melt semi-solid compositions, methods of making same and methods of using same
EP2007361A1 (en) Film-coated solid dosage forms
JP2818220B2 (en) Composition containing water-containing organic solvent extract for food, composition containing water-containing organic solvent extract for medicine, and methods for producing them
KR20100098612A (en) Improved tablet coating
PL209144B1 (en) Solid orally-dispersible pharmaceutical formulation
HU208488B (en) Process for producing sucralfat-containing chewing tablet
JP3261331B2 (en) Soft capsule for chewing
JP2002193839A (en) Cocoa pharmaceutical preparation
JP2025175057A (en) Tablet and method for producing tablet
WO2005049048A1 (en) Fiber rich fraction of trigonella foenum-graecum and its use as a pharmaceutcal excipient
US20040228932A1 (en) Pharmaceutical excipient
JPH02221232A (en) Readily drinkable medicine composition
JP5478170B2 (en) Orally disintegrating tablets
JP2025105167A (en) Coated solid preparation, coating composition, and method for improving ease of ingestion of solid preparation
JP4634589B2 (en) Food or pharmaceutical ready-to-use agent
JPWO2006129668A1 (en) Sugar-coated pills